<DOC>
	<DOCNO>NCT02183649</DOCNO>
	<brief_summary>The primary objective trial investigate potential effect pentoxyverine ECGs healthy subject . A secondary objective exploration safety tolerability . Pharmacokinetics ( PK ) investigate necessary explanation ECG effect .</brief_summary>
	<brief_title>Tolerability Potential ECG Effects After Single Oral Dose Pentoxyverine Citrate Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Carbetapentane</mesh_term>
	<criteria>1 . Healthy male female subject accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) ) 12lead ECG , clinical laboratory test 2 . Age ≥21 ≤45 year 3 . Body Mass Index ( BMI ) ≥18.5 ≤29.9 kg/m² 4 . Signed date write informed consent prior admission study accordance GCP local legislation . 1 . Any finding medical examination ( include BP , PR , ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial 10 . Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial 11 . Participation another trial investigational drug within two month prior administration trial 12 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 13 . Inability refrain smoke trial day 14 . Alcohol abuse ( 60 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . Excessive physical activity ( within one week prior administration trial ) 18 . Any laboratory value outside reference range clinical relevance 19 . Inability comply dietary regimen trial site 20 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) ; 21 . A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>